Anti-HIV1 Library
ChemDiv’s Anti-HIV1 Library contains 21,000 compounds.
One of the obstacles to the treatment of the human immunodeficiency virus (HIV) is its high genetic variability. HIV can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is the most common and pathogenic strain of the virus. Scientists divide HIV-1 into a major group (Group M) and two or more minor groups, namely Group N, O and possibly a group P. Each group is believed to represent an independent transmission of SIV into humans. Isolates of HIV-1 and HIV-2 with resistance to antiretroviral drugs arise through natural selection and genetic mutations, which have been tracked and analyzed.
AIDS-related mortality has declined considerably because of the widespread application of combination antiretroviral therapy. However, pretreatment resistance to antiretroviral drugs has been reported in many countries. Therefore, the development of anti-HIV drugs against new targets and with high genetic barriers to resistance is urgently needed. The usage of a small-molecule drug can help overcome several of the disadvantages of an antibody-based drug, such as high cost of production, cold-chain transportation, and a requirement for delivery by injection. [1]
[1] Su, S., & Jiang, S. (2020). Anti-HIV agents inspired by antibodies. Nature Chemical Biology, 16(5), 483–484. doi:10.1038/s41589-020-0521-1
One of the obstacles to the treatment of the human immunodeficiency virus (HIV) is its high genetic variability. HIV can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is the most common and pathogenic strain of the virus. Scientists divide HIV-1 into a major group (Group M) and two or more minor groups, namely Group N, O and possibly a group P. Each group is believed to represent an independent transmission of SIV into humans. Isolates of HIV-1 and HIV-2 with resistance to antiretroviral drugs arise through natural selection and genetic mutations, which have been tracked and analyzed.
AIDS-related mortality has declined considerably because of the widespread application of combination antiretroviral therapy. However, pretreatment resistance to antiretroviral drugs has been reported in many countries. Therefore, the development of anti-HIV drugs against new targets and with high genetic barriers to resistance is urgently needed. The usage of a small-molecule drug can help overcome several of the disadvantages of an antibody-based drug, such as high cost of production, cold-chain transportation, and a requirement for delivery by injection. [1]
[1] Su, S., & Jiang, S. (2020). Anti-HIV agents inspired by antibodies. Nature Chemical Biology, 16(5), 483–484. doi:10.1038/s41589-020-0521-1